Biology subjects

O'Brien, N. L.

Publications and source records attributed to O'Brien, N. L..

3 recordsLinked to original sources

bioRxiv2026

C9ORF72-derived polyGR polypeptides disrupt passive nucleocytoplasmic transport by tuning protein affinity for the nuclear pore barrier

Nucleocytoplasmic partitioning is an essential determinant of eukaryotic cellular function, governed by the nuclear pore complex, a molecular portal filled by a disordered phenylalanine-glycine (FG)-rich phase that governs selective entry and exit. Disruption of nucleocytoplasmic partitioning is seen across many different diseases, including viral infection, cancer, and neurodegeneration. However, what determines whether a given protein mislocalises when nucleocytoplasmic transport is disrupted remains unknown. This question is central to amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD), where cytosolic mislocalisation of the nuclear RNA-binding protein TDP-43 is a defining pathological feature. The most common genetic cause of these diseases is a G4C2 repeat expansion in the gene C9ORF72, which produces aberrant neurotoxic polypeptides that induce nucleocytoplasmic transport defects. Here, we show how the highly toxic poly(glycine-arginine/GR) polypeptide engages the nuclear pore FG-rich selectivity barrier and retunes passive nucleocytoplasmic transport according to client surface chemistry. Using coarse-grained simulations, in vitro FG-phase reconstitution and human cell lines and neurons, we find that polyGR produces a non-linear, biphasic modulation of nuclear pore passage. Proteins with low affinity for the FG phase are unaffected, whereas proteins with higher affinity due to solvent-exposed hydrophobic residues exhibit enhanced transport up to a critical threshold, beyond which highly hydrophobic proteins experience transport suppression, cytoplasmic accumulation and aggregation. Together, these findings establish how disease-associated polypeptides retune the physicochemical rules governing passive nuclear pore transport, leading to biphasic outcomes determined by protein surface chemistry that alter protein compartmentalisation and aggregation. This provides a biophysical mechanism by which polyGR drives selective protein vulnerability to nuclear pore dysfunction in C9ORF72-associated ALS/FTD.

cell biology↗

bioRxiv2025

CRISPR/Cas9-mediated generation of a de novo C9ORF72 knock-in isogenic iPSC cell bank to model ALS and FTD

BackgroundThe pathogenic G4C2 repeat expansion in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Studies focused on delineating the underlying perturbed mechanisms resulting from this genetic mutation are often confounded by the heterogeneity present in current disease models, such as patient-derived iPSC lines, with estimations of up to 50% of the variation in iPSC cell phenotypes resulting from inter-individual differences. Isogenic models, in which the pathogenic mutation is introduced into a defined genetic background, offer a powerful approach to isolating mutation-specific effects and enable high-resolution comparison across distinct ALS/FTD-associated mutations. Such models are essential for uncovering convergent disease mechanisms and improving reproducibility in ALS/FTD research. MethodsA two-step scarless CRISPR/Cas9 genome editing strategy was used to generate isogenic human iPSC lines carrying a de novo knock-in of a disease-length G4C2 repeat expansion in the C9ORF72 locus. The resulting lines underwent thorough quality control and were differentiated into lower motor neurons and assessed for the presence of key ALS/FTD pathologies, including changes to C9ORF72 mRNA and protein expression, RNA foci and dipeptide repeat proteins. ResultsTwo C9ORF72 knock-in iPSC lines were generated with 631 and 600 G4C2 repeats, alongside an isogenic genome editing control line. The C9ORF72 G4C2 repeat expansion knock-in iPSC lines exhibit both loss-of-function and gain-of-function pathological features characteristic of ALS/FTD. Compared to the parental wild-type KOLF2.1J line and isogenic (wild-type) CRISPR control line, these exhibit a significant reduction in C9ORF72 mRNA and protein levels, the presence of RNA foci accumulation, and a marked increase in poly(GA) and poly(GP) dipeptide repeat protein levels in iPSCs and motor neurons. ConclusionsThis is one of the first reports of a successful knock-in of the pathogenic C9ORF72 G4C2 repeat expansion into a human iPSC line, establishing a genetically defined and physiologically relevant model of ALS/FTD. These isogenic lines recapitulate both key loss- and gain-of-function disease pathologies, providing a crucial complement to existing patient-derived iPSC banks. By eliminating confounding genetic background variability, these cell lines will enable more precise interrogation of C9ORF72-linked pathomechanisms and offer a robust platform for comparative studies across the ALS and FTD spectrum, mechanistic investigations, and future therapeutic targeting with enhanced translational relevance.

neuroscience↗

bioRxiv2020

Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene-dose-sensitive AD-suppressor in human brain

A population of >6 million people worldwide at high risk of Alzheimers disease (AD) are those with Down Syndrome (DS, caused by trisomy 21 (T21)), 70% of whom develop dementia during lifetime, caused by an extra copy of {beta}-amyloid-(A{beta})-precursor-protein gene. We report AD-like pathology in cerebral organoids grown in vitro from non-invasively sampled strands of hair from 71% of DS donors. The pathology consisted of extracellular diffuse and fibrillar A{beta} deposits, hyperphosphorylated/pathologically conformed Tau, and premature neuronal loss. Presence/absence of AD-like pathology was donor-specific (reproducible between individual organoids/iPSC lines/experiments). Pathology could be triggered in pathology-negative T21 organoids by CRISPR/Cas9-mediated elimination of the third copy of chromosome-21-gene BACE2, but prevented by combined chemical {beta} and {gamma}-secretase inhibition. We found that T21-organoids secrete increased proportions of A{beta}-preventing (A{beta}1-19) and A{beta}-degradation products (A{beta}1-20 and A{beta}1-34). We show these profiles mirror in cerebrospinal fluid of people with DS. We demonstrate that this protective mechanism is mediated by BACE2-trisomy and cross-inhibited by clinically trialled BACE1-inhibitors. Combined, our data prove the physiological role of BACE2 as a dose-sensitive AD-suppressor gene, potentially explaining the dementia delay in [~]30% of people with DS. We also show that DS cerebral organoids could be explored as pre-morbid AD-risk population detector and a system for hypothesis-free drug screens as well as identification of natural suppressor genes for neurodegenerative diseases.

neuroscience↗